We previously showed that G-CSF polarizes human T-cell and DC function towards a tolerogenic profile, implying that G-CSF-mobilized cell therapy products may be intrinsically less capable of inducing uncontrollable GVHD [17,19,41]. The gene discussed is CSF3; the disease is graft versus host disease.